Skip to content
IL-23p19 agents in Ulcerative Colitis Expert Video
April 7, 2025 ~ Robert Battat, MD
**Pre-assessment**
Before you participate in this activity, please take this pre-assessment.
Taking this pre-assessment does not immediately qualify learners to earn credit.
Certificates of credit will only be sent to learners who also receive a passing score on the post-test (separate from this survey), and fill out the evaluation form and application for credit.
*
1.
Where are you in your career?
(Required.)
IBD Specialist
General GI
Fellow/Trainee
APP
PharmD
Other (please specify)
*
2.
Patient with moderate to severe ulcerative colitis, initially treated with IFX now losing response despite adequate therapeutic drug level.
Which therapy/MOA is as effective in bio-exposed patients as it is in bio-naïve patients in the RCT that led to drug approval?
(Required.)
Adalimumab
Vedolizumab
Mirikizumab, Guselkumab
None of the above
*
3.
At week 52 what is the percentage of patients treated with Mirikizumab for moderate to severe UC who achieved endoscopic improvement defined as an endoscopic Mayo score of 0 or 1 without friability (extra-point: delta Miri vs placebo induction)?
(Required.)
38% (delta 7)
48 % (delta 17)
58% (delta 27)
4.
Completing this pre-survey does not qualify you for a CME certificate. Only after completing the post-survey & evaluation form will a certificate be issued.
First & Last Name
🔗
Proceed to activity on X/MondayNightIBD
🔗 Proceed to activity post-survey
(post-survey completion must occur on or after activity launch date and prior to activity expiration date to be valid for claiming credit)
